Diana T. Y.
- Country
- Bulgaria
- Department
- Endocrinology and Metabolic Diseases Consulting Room
Research Overview
- A Phase 3 Study to Compare the Efficacy and Safety of KAI-9531 Versus Semaglutide in Participants Living with Obesity Without Diabetes
- Phase 3 Randomized Double-Blind Placebo-Controlled Study of KAI-9531 in Adults With Obesity or Overweight and Diabetes
- Randomized Study of Cagrilintide + Semaglutide Combination vs Semaglutide Monotherapy for Weight Loss in Adults with Obesity (± Type 2 Diabetes)
Data & Insights
Has run more than one trial at 36 of 312 partner sites.
Specializations
Atherosclerotic cardiovascular disease and cardiovascular risk reduction
Diana Teneva-Yankova is involved in clinical research focused on atherosclerotic cardiovascular disease, established cardiovascular disease, and broader high cardiovascular risk populations. Her trial portfolio also includes studies addressing cardiovascular disease in the setting of chronic kidney disease and systemic inflammation.
- Major adverse cardiovascular events
- Stroke prevention in atrial fibrillation
- Inflammatory cardiovascular risk
Her research landscape includes therapeutic strategies aimed at reducing event burden in patients with hypertension, type 2 diabetes, and coexisting cardiovascular disease.
Heart failure and cardiometabolic overlap
Her clinical trial activity extends to heart failure populations, including HFpEF, HFmrEF, and reduced left ventricular function, with a strong emphasis on patients who also have obesity or type 2 diabetes. The research focus includes symptomatic and event-driven heart failure outcomes.
- Heart failure hospitalization
- Urgent heart failure visits
- Obesity-related heart failure
This work reflects interest in therapies that connect cardiometabolic disease management with prevention of worsening heart failure.
Hypertriglyceridemia and lipid disorder management
A major area of interest is the treatment of hypertriglyceridemia, including severe hypertriglyceridemia and persistent triglyceride elevation. Her trial involvement covers lipid-lowering approaches designed to address both biochemical control and long-term safety in patients with marked triglyceride abnormalities.
- Severe hypertriglyceridemia
- Triglyceride lowering
- Hypertriglyceridemia safety
Her research portfolio also includes patients with hypertriglyceridemia alongside obesity and cardiovascular disease, highlighting a cardiometabolic treatment focus.
Obesity and metabolic disease
Diana Teneva-Yankova is active in studies centered on obesity and overweight, including participants with and without diabetes. Her research interests include body weight reduction and metabolic improvement in populations where excess adiposity contributes to cardiovascular and glycemic risk.
- Body weight reduction
- Glycemic control
- Obesity with diabetes
This area of work aligns with broader efforts to address cardiometabolic disease through therapies targeting weight and glucose-related outcomes.
Hypertension, renal disease, and systemic inflammation
Her clinical research also includes hypertension and its relationship with cardiovascular disease, high cardiovascular risk, and chronic kidney disease. These studies place emphasis on patients with overlapping vascular and renal risk profiles, including those with inflammatory disease features.
- Blood pressure control
- Cardiorenal risk
- Systemic inflammation
Her trial activity in this area contributes to therapeutic development for patients whose cardiovascular burden is amplified by renal impairment and metabolic comorbidity.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.